United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp lessened its stake in United Therapeutics Co. (NASDAQ:UTHR – Get Rating) by 22.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 606,532 shares of the biotechnology company’s stock after selling 174,377 shares during the quarter. Bank of New York Mellon Corp owned about 1.33% of United Therapeutics worth $126,995,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Bridgefront Capital LLC acquired a new position in shares of United Therapeutics in the 3rd quarter valued at $307,000. Teachers Retirement System of The State of Kentucky acquired a new position in shares of United Therapeutics in the 3rd quarter valued at $9,384,000. Seaport Global Advisors LLC boosted its holdings in shares of United Therapeutics by 23.2% in the 3rd quarter. Seaport Global Advisors LLC now owns 675 shares of the biotechnology company’s stock valued at $141,000 after purchasing an additional 127 shares during the last quarter. Glenmede Trust Co. NA acquired a new position in shares of United Therapeutics in the 3rd quarter valued at $1,472,000. Finally, Captrust Financial Advisors boosted its holdings in shares of United Therapeutics by 19.6% in the 3rd quarter. Captrust Financial Advisors now owns 167,390 shares of the biotechnology company’s stock valued at $35,048,000 after purchasing an additional 27,467 shares during the last quarter. Institutional investors and hedge funds own 95.63% of the company’s stock.

Insider Transactions at United Therapeutics

In other news, EVP Paul A. Mahon sold 6,000 shares of the business’s stock in a transaction dated Thursday, March 16th. The shares were sold at an average price of $214.39, for a total value of $1,286,340.00. Following the completion of the sale, the executive vice president now owns 36,599 shares of the company’s stock, valued at approximately $7,846,459.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Louis W. Sullivan sold 700 shares of United Therapeutics stock in a transaction dated Tuesday, January 3rd. The shares were sold at an average price of $276.26, for a total value of $193,382.00. Following the completion of the transaction, the director now directly owns 12,180 shares of the company’s stock, valued at approximately $3,364,846.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction dated Thursday, March 16th. The shares were sold at an average price of $214.39, for a total transaction of $1,286,340.00. Following the completion of the transaction, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at $7,846,459.61. The disclosure for this sale can be found here. In the last 90 days, insiders sold 187,400 shares of company stock valued at $48,069,013. Insiders own 12.40% of the company’s stock.

United Therapeutics Stock Performance

United Therapeutics stock opened at $219.73 on Friday. The firm’s fifty day moving average price is $250.23 and its 200 day moving average price is $246.69. The company has a market capitalization of $10.17 billion, a price-to-earnings ratio of 14.63, a price-to-earnings-growth ratio of 1.61 and a beta of 0.62. United Therapeutics Co. has a 12-month low of $173.21 and a 12-month high of $283.09. The company has a debt-to-equity ratio of 0.17, a current ratio of 9.85 and a quick ratio of 9.55.

United Therapeutics (NASDAQ:UTHR – Get Rating) last released its earnings results on Wednesday, February 22nd. The biotechnology company reported $2.67 earnings per share for the quarter, missing the consensus estimate of $4.12 by ($1.45). The company had revenue of $491.50 million during the quarter, compared to the consensus estimate of $519.20 million. United Therapeutics had a return on equity of 16.30% and a net margin of 37.56%. United Therapeutics’s revenue for the quarter was up 18.4% on a year-over-year basis. During the same period in the previous year, the firm posted $2.35 EPS. On average, research analysts forecast that United Therapeutics Co. will post 17.95 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. UBS Group assumed coverage on shares of United Therapeutics in a report on Tuesday, December 6th. They set a “buy” rating and a $320.00 target price on the stock. Morgan Stanley reduced their target price on shares of United Therapeutics from $330.00 to $320.00 and set an “overweight” rating on the stock in a report on Thursday, February 23rd. HC Wainwright restated a “buy” rating and set a $300.00 target price on shares of United Therapeutics in a report on Thursday, February 23rd. StockNews.com assumed coverage on shares of United Therapeutics in a report on Thursday. They set a “buy” rating on the stock. Finally, Argus lifted their target price on shares of United Therapeutics from $250.00 to $300.00 and gave the company a “buy” rating in a report on Wednesday, January 11th. Two investment analysts have rated the stock with a sell rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $291.55.

United Therapeutics Company Profile

(Get Rating)

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.